These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34951369)

  • 1. Precision Medicine in Patients with Differential Diabetic Phenotypes: Novel Opportunities from Network Medicine.
    Napoli C; Benincasa G; Ellahham S
    Curr Diabetes Rev; 2022; 18(8):e221221199301. PubMed ID: 34951369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine.
    Sousa M; Bruges-Armas J
    Curr Diabetes Rev; 2020; 16(8):807-819. PubMed ID: 31886753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients' response to gliclazide-modified-release-treated.
    Huang X; Zhou Y; Tang H; Liu B; Su B; Wang Q
    J Biomed Inform; 2021 Jun; 118():103796. PubMed ID: 33932596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease.
    Infante T; Del Viscovo L; De Rimini ML; Padula S; Caso P; Napoli C
    J Atheroscler Thromb; 2020 Apr; 27(4):279-302. PubMed ID: 31723086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity.
    Bowman P; Flanagan SE; Hattersley AT
    J Diabetes Res; 2018; 2018():3061620. PubMed ID: 30599002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
    Meyer RJ
    Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine in diabetes.
    Malandrino N; Smith RJ
    Clin Chem; 2011 Feb; 57(2):231-40. PubMed ID: 21127150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.
    Venkatachalapathy P; Padhilahouse S; Sellappan M; Subramanian T; Kurian SJ; Miraj SS; Rao M; Raut AA; Kanwar RK; Singh J; Khadanga S; Mondithoka S; Munisamy M
    Pharmgenomics Pers Med; 2021; 14():1441-1455. PubMed ID: 34803393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope.
    Aghaei Meybodi HR; Hasanzad M; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):166-174. PubMed ID: 28282717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Need for Precision Medicine to be Applied to Diabetes.
    Klonoff DC; Florez JC; German M; Fleming A
    J Diabetes Sci Technol; 2020 Nov; 14(6):1122-1128. PubMed ID: 31903769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human genetics of diabetes mellitus in Taiwan.
    Chen PL; Yang WS
    Front Biosci (Landmark Ed); 2009 Jan; 14(12):4535-45. PubMed ID: 19273368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
    Dalan R; Liuh Ling G
    Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative network stratification analysis for identifying functional interpretable network biomarkers.
    Zhang C; Liu J; Shi Q; Zeng T; Chen L
    BMC Bioinformatics; 2017 Mar; 18(Suppl 3):48. PubMed ID: 28361683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network medicine and type 2 diabetes mellitus: insights into disease mechanism and guide to precision medicine.
    Loscalzo J
    Endocrine; 2019 Dec; 66(3):456-459. PubMed ID: 31410748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and clinical characteristics of maturity-onset diabetes of the young.
    Giuffrida FM; Reis AF
    Diabetes Obes Metab; 2005 Jul; 7(4):318-26. PubMed ID: 15955117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized epigenetic management of diabetes.
    Fodor A; Cozma A; Karnieli E
    Per Med; 2017 Nov; 14(6):531-549. PubMed ID: 29749858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.
    Mannino GC; Andreozzi F; Sesti G
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3109. PubMed ID: 30515958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes.
    Wang Y; Gao Y; Cai X; Chen L; Zhou L; Ma Y; Gong S; Han X; Ji L
    J Diabetes Res; 2019; 2019():1747684. PubMed ID: 31485449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of Type 2 Diabetes: Opportunities for Precision Medicine: JACC Focus Seminar.
    Kim DS; Gloyn AL; Knowles JW
    J Am Coll Cardiol; 2021 Aug; 78(5):496-512. PubMed ID: 34325839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects.
    Khatami F; Mohajeri-Tehrani MR; Tavangar SM
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):719-731. PubMed ID: 31122183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.